Mizuho Securities Assumes CASI Pharmaceuticals (CASI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts CASI Hot Sheet
Price: $0.21 --0%
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Mizuho Securities analyst Mara Goldstein assumes coverage on CASI Pharmaceuticals (NASDAQ: CASI) with a Buy rating and a price target of $3.80.
For an analyst ratings summary and ratings history on CASI Pharmaceuticals click here. For more ratings news on CASI Pharmaceuticals click here.
Shares of CASI Pharmaceuticals closed at $0.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Assumes MiNK Therapeutics (INKT) at Buy
- Bernstein SocGen Group Starts Abbott India Ltd (BOOT:IN) at Market Perform
- Cantor Fitzgerald Starts Netskope (NTSK) at Overweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
Mara GoldsteinSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
